[HTML][HTML] Antigenic evolution of SARS coronavirus 2
AZ Mykytyn, RAM Fouchier, BL Haagmans - Current Opinion in Virology, 2023 - Elsevier
SARS coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, emerged in China in
December 2019. Vaccines developed were very effective initially, however, the virus has …
December 2019. Vaccines developed were very effective initially, however, the virus has …
COVID‐19 and plasma cells: Is there long‐lived protection?
DC Nguyen, PA Lamothe, MC Woodruff… - Immunological …, 2022 - Wiley Online Library
Summary Infection with SARS‐CoV‐2, the etiology of the ongoing COVID‐19 pandemic, has
resulted in over 450 million cases with more than 6 million deaths worldwide, causing global …
resulted in over 450 million cases with more than 6 million deaths worldwide, causing global …
Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants
Current coronavirus disease 2019 (COVID-19) vaccines effectively reduce overall morbidity
and mortality and are vitally important to controlling the pandemic. Individuals who …
and mortality and are vitally important to controlling the pandemic. Individuals who …
[HTML][HTML] Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with
antigenic changes in the spike protein are neutralized less efficiently by serum antibodies …
antigenic changes in the spike protein are neutralized less efficiently by serum antibodies …
[HTML][HTML] Reduced neutralisation of the Delta (B. 1.617. 2) SARS-CoV-2 variant of concern following vaccination
Vaccines are proving to be highly effective in controlling hospitalisation and deaths
associated with SARS-CoV-2 infection but the emergence of viral variants with novel …
associated with SARS-CoV-2 infection but the emergence of viral variants with novel …
An aluminum hydroxide: CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice
E Nanishi, F Borriello, TR O'Meara… - Science translational …, 2021 - science.org
Global deployment of vaccines that can provide protection across several age groups is still
urgently needed to end the COVID-19 pandemic, especially in low-and middle-income …
urgently needed to end the COVID-19 pandemic, especially in low-and middle-income …
[HTML][HTML] Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection
SARS-CoV-2 infection is generally mild or asymptomatic in children but a biological basis for
this outcome is unclear. Here we compare antibody and cellular immunity in children (aged …
this outcome is unclear. Here we compare antibody and cellular immunity in children (aged …
Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission
SARS-CoV-2 has caused morbidity and mortality across the globe. As the virus spreads,
new variants are arising that show enhanced capacity to bypass preexisting immunity. To …
new variants are arising that show enhanced capacity to bypass preexisting immunity. To …
[HTML][HTML] Population immunity predicts evolutionary trajectories of SARS-CoV-2
M Meijers, D Ruchnewitz, J Eberhardt, M Łuksza… - Cell, 2023 - cell.com
The large-scale evolution of the SARS-CoV-2 virus has been marked by rapid turnover of
genetic clades. New variants show intrinsic changes, notably increased transmissibility, and …
genetic clades. New variants show intrinsic changes, notably increased transmissibility, and …
Neutralization of SARS-CoV-2 variants in transplant recipients after two and three doses of mRNA-1273 vaccine: secondary analysis of a randomized trial
Background: COVID-19 is more severe in transplant recipients. Variants of concern have
supplanted wild-type virus. In transplant recipients, data are limited on 2-dose or 3-dose …
supplanted wild-type virus. In transplant recipients, data are limited on 2-dose or 3-dose …